News Troubled 23andMe is exploring a sale of the business Genetic testing specialist 23andMe has launched a strategic review that could result in a sale of the company.
News Sage rejects Biogen takeover and launches review Sage Therapeutics has unanimously rejected Biogen's acquisition offer of around $469 million, saying it "significantly undervalues" the company.
R&D 5 takeaways from JP Morgan 2025 I’m back from another week in San Francisco, where as usual I heard from experts and prognosticators about their expectations for the coming year in biotech.
News Sun Pharma unit poised to buy Canadian biotech Antibe Sun Pharma's Taro unit has made a bid to acquire Canadian biotech Antibe, a developer of drugs for pain and inflammation.
News Sage sues Biogen after unsolicited takeover bid Sage Therapeutics has left its view of Biogen's recent takeover bid in little doubt – it has just filed a lawsuit seeking to block the deal.
News Lilly nets Scorpion cancer drug in $2.5bn licensing deal Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a breast cancer therapy being developed by Scorpion Therapeutics.
R&D Ben Sidders on integrating causality in AI for R&D success Ben Sidders, chief scientific officer at Biorelate, discusses leveraging advanced data science methods to transform the focus and impact of R&D.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face